A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Eisai Inc.
PMV Pharmaceuticals, Inc
NiKang Therapeutics, Inc.
Kivu Bioscience Inc.
NeoImmuneTech
Alterome Therapeutics, Inc.
BeOne Medicines
Genmab
Eli Lilly and Company
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Genmab
Accent Therapeutics
Seagen Inc.
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
A2 Biotherapeutics Inc.
Exscientia AI Limited
Normunity AccelCo, Inc.
Eli Lilly and Company
NiKang Therapeutics, Inc.
SystImmune Inc.
Eli Lilly and Company
Radiopharm Theranostics, Ltd
Eli Lilly and Company
Ocellaris Pharma, Inc.
Seagen Inc.
Elephas
Fusion Pharmaceuticals Inc.
Apollo Therapeutics Ltd
Innate Pharma
Novartis
OncoNano Medicine, Inc.
I-Mab Biopharma US Limited
NeoTX Therapeutics Ltd.
Avenzo Therapeutics, Inc.
Merck Sharp & Dohme LLC
BicycleTx Limited
Bolt Biotherapeutics, Inc.
Pfizer
BicycleTx Limited
Volastra Therapeutics, Inc.
Mersana Therapeutics
Rondo Therapeutics
NiKang Therapeutics, Inc.
Nurix Therapeutics, Inc.
TCR2 Therapeutics
Exelixis
Adcentrx Therapeutics